aTyr Pharma’s (LIFE) “Buy” Rating Reaffirmed at HC Wainwright

aTyr Pharma (NASDAQ:LIFE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $35.00 price objective on the biotechnology company’s stock.

Separately, Royal Bank of Canada dropped their price objective on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $23.67.

aTyr Pharma Price Performance

Shares of NASDAQ:LIFE traded up $0.01 on Friday, hitting $1.61. The company had a trading volume of 258,118 shares, compared to its average volume of 498,541. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.02. The company has a market cap of $109.38 million, a PE ratio of -1.68 and a beta of 1.27. aTyr Pharma has a 52-week low of $1.08 and a 52-week high of $2.70. The business has a 50 day moving average of $1.77 and a 200 day moving average of $1.55.

aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.11 million. As a group, equities analysts anticipate that aTyr Pharma will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

Large investors have recently modified their holdings of the stock. FMR LLC grew its stake in shares of aTyr Pharma by 5.1% in the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock valued at $13,520,000 after buying an additional 413,162 shares in the last quarter. Pale Fire Capital SE purchased a new position in aTyr Pharma in the third quarter valued at about $88,000. GSA Capital Partners LLP boosted its holdings in aTyr Pharma by 105.3% in the first quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 114,983 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new position in aTyr Pharma in the first quarter valued at about $117,000. Finally, Granite Bay Wealth Management LLC purchased a new position in aTyr Pharma in the fourth quarter valued at about $25,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.